Establishment of local and switchable innate immune activation by novel nucleic acid adjuvant
Project/Area Number |
25640084
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor therapeutics
|
Research Institution | Hokkaido University |
Principal Investigator |
TAKAOKA Akinori 北海道大学, 遺伝子病制御研究所, 教授 (30323611)
|
Co-Investigator(Renkei-kenkyūsha) |
SATO Seiichi 北海道大学, 遺伝子病制御研究所, 助教 (60459724)
KAMEYAMA Takeshi 北海道大学, 遺伝子病制御研究所, 助教 (40569505)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 自然免疫 / 核酸 / アジュバント / 自然免疫活性化 / 核酸アジュバント / 放射線照射 / 抗腫瘍効果 |
Outline of Final Research Achievements |
Adjuvant is an important component for effective vaccination and antitumor therapy. Establishment of local and switchable adjuvant is considered to be an efficient strategy to reduce side effects and efficiently activate innate immune responses. The purpose of this study is the establishment of a novel nucleic acid adjuvant that can trigger the activation of innate immune system in response to X-ray irradiation. In this study, type-C CpG ligands contained with cystamine-modified cytosine were used and showed its structural change by X-ray irradiation, albeit their low efficiency. These results showed these ligands could be a switchable activator and further investigation will be needed to improve their efficiency.
|
Report
(3 results)
Research Products
(3 results)